Exabis Library
Welcome to the e-CCO Library!
OP002: Epigenetic biomarkers to detect ulcerative colitis-associated neoplasia: results from phase I of the ENDCAP-C study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP002: Histopathological response and remission after dual topical application of the Toll-like receptor 9 agonist DIMS0150 in patients with moderate-to-severe ulcerative colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP003: Increased risk of acute arterial events in young patients with severely active Inflammatory Bowel Disease: A nationwide French cohort study
2017
ECCO'17 Barcelona
Wednesday, 15 March 2017, 1:43 PM by ECCO Administrator
1
OP003: Increased risk of acute arterial events in young patients with severely active inflammatory bowel disease: a nationwide French cohort study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP003: Predicting short and medium-term efficacy of the biosimilar infliximab: trough levels/do anti-drug antibody’s or clinical/biochemical markers play a more important role?
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP003: Temporal changes in immune pathways with consecutive biological therapies as measured by serum proteomics
2018
ECCO'18 Vienna
Friday, 23 March 2018, 12:23 PM
1
OP003: Temporal changes in immune pathways with consecutive biological therapies as measured by serum proteomics
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP004: Gene expression profiling indicates similar molecular pathways are active in adult and paediatric Crohn’s disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP004: Resetting of the mucosal T cell repertoire after hematopoietic stem cell transplantation in refractory Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP004: Resetting of the mucosal T cell repertoire after hematopoietic stem cell transplantation in refractory Crohn‘s Disease
2017
ECCO'17 Barcelona
Wednesday, 15 March 2017, 1:48 PM by ECCO Administrator
1
OP004: The TLR9 agonist cobitolimod induces anti-inflammatory effects and balances the Th17/T-reg cell response in Ulcerative Colitis
2018
ECCO'18 Vienna
Friday, 9 November 2018, 10:21 AM by Lindley Fritze
OP004: The TLR9 agonist cobitolimod induces anti-inflammatory effects and balances the Th17/T-reg cell response in ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP005: A variable number of tandem repeat polymorphism in the promotor region of the neonatal Fc receptor affects anti-tumour necrosis factor serum levels in inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP005: Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP005: The PROSIT cohort of infliximab biosimilar in IBD: A prolonged follow-up on the efficacy and safety across Italy
2017
ECCO'17 Barcelona
Wednesday, 15 March 2017, 1:53 PM by ECCO Administrator
1
OP005: The PROSIT cohort of infliximab biosimilar in IBD: a prolonged follow-up on the efficacy and safety across Italy
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP006: Apremilast for active Ulcerative Colitis: A phase 2, randomised, double-blind, placebo-controlled induction study
2018
ECCO'18 Vienna
Friday, 23 March 2018, 12:23 PM
1
OP006: Autophagy regulates dendritic cell migration through Rac1: implications for thiopurine therapy
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP006: Correlation of durability of response, serum trough concentrations and outcome parameters: Long-term follow-up of the Trough Concentration Adapted Infliximab Treatment (TAXIT) trial
2017
ECCO'17 Barcelona
Wednesday, 15 March 2017, 1:55 PM by ECCO Administrator
1
OP006: Correlation of durability of response, serum trough concentrations and outcome parameters: long-term follow-up of the Trough Concentration Adapted Infliximab Treatment (TAXIT) trial
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM